Shares of multi-specialty healthcare company Hims & Hers Health (HIMS) gained more than 25% over the past month, with increased insider trading sparking investor interest. However, given its bleak financials,...
Hims & Hers has the growth and the cash to last.
Telehealth stocks have declined from the Covid-induced highs and are expected to plunge further due to the nation’s return to normalcy. Moreover, the current macroeconomic headwinds are expected to put...
With U.S. inflation hitting a 40-year high, investors are now expecting the U.S. Federal Reserve to announce aggressive interest rate hikes. Amid the broader market sell-off and persistent market headwinds,...
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, is today announcing...
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, is today revealing...
The Federal Reserve's interest rate increases to reduce inflationary pressure, and recession fears, have driven many SPAC stocks to significant price declines of late. The shares of Hims & Hers Health...
Investors could be overlooking an attractive investment opportunity with Hims & Hers right now.
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 11.11% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals and provides access to related prescription...
